Business Wire

ÓSKARE CAPITAL SAS Launches ÓSKARE Fund I Focusing on Innovative European Companies in the Medical Cannabinoid Industry

Share

ÓSKARE CAPITAL SAS today launches ÓSKARE Fund I together with cannabinoid industry veteran Bruce Linton. The EU based fund targets next generation cannabinoid therapies and related industry infrastructure, leveraging the expertise and track record of the founding team in medicine, engineering, chemistry, venture capital, and intellectual property.

“Based on my partnership with the ÓSKARE CAPITAL team over the last 9 months, I am convinced that Europe has the optimal regulatory and research environment to build the future key players in the global medical cannabinoid industry,” said Bruce Linton, Co-founder and non- Executive Chairman, ÓSKARE CAPITAL, and former CEO and Founder, Canopy Growth. "The ÓSKARE CAPITAL team’s strong scientific background and proven track record in pharma, venture capital and IP protection leverages proprietary deal flow and knowledge of the ecosystem to be successful".

The fund will invest in a diversified portfolio of companies with disruptive technology and strong barriers to entry. The team is supported by a highly experienced senior advisory board (https://oskarecapital.com/team/) that provides critical expertise and expands its network. ÓSKARE Fund I is ESG compatible.

Medical grade cannabinoid-based products are already approved and used in Europe to treat conditions such as epilepsy, multiple sclerosis and chronic pain. Now the science and the medical community are driving opportunities in human as well as animal health and wellness.

The team at ÓSKARE CAPITAL has access to leading research teams and companies that have identified new cannabinoid molecules and formulations with therapeutic potential for medical conditions such as anxiety and depression, cancer, autism, ADHD, cardiovascular and inflammatory skin conditions, among others. The fund will invest in the entire value chain as well as look to valorise hemp and cannabis biomass for new sustainable material applications.

The team has already performed a first investment in Denmark’s Octarine Bio.

Innovation and R&D are at the core of EU and UK value generation and core to the Fund opportunity. Cannabinoids will disrupt global markets from food to pharma and ÓSKARE CAPITAL will be the early investor on this wave.

About ÓSKARE CAPITAL SAS – oskarecapital.com

ÓSKARE CAPITAL SAS is a French company which has the French status of CIF (Financial Investment Advisor), ORIAS number 20001206 and regulated by the AMF.

About ÓSKARE FUND I

ÓSKARE Fund I, advised by ÓSKARE CAPITAL SAS, is set up so that investors can readily access innovative opportunities in this space with the protection and transparency an AIFM compatible fund provides. Regulated by the Central Bank of Ireland, Crossroads Capital Management Limited will act as an alternative investment fund manager.

About Crossroads Capital Management Limited – www.crossroadscapital.ie

Crossroads Capital Management Limited, majority owned by Hauck & Aufhäuser Fund Services S.A., is authorised and regulated by the Central Bank of Ireland as a UCITS management company and alternative investment fund manager (AIFM).

This press release is not a marketing communication in the European Union member states or non-member states. This press release is not an offer of securities, products, instruments or services for sale in the United States. We do not make representation that information presented is appropriate for use in all jurisdictions.

Contact information

Press Contact: email - alex@oskarecapital.com, tel - +33 6 68 29 57 94

Prospective fund investors contact: Gaetano INSALACO - gaetano@oskarecapital.com

Companies seeking investment contact: Alexandre OUIMET-STORRS - alex@oskarecapital.com
or Nicola BROUGHTON - nicola@oskarecapital.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bacardi Limited Welcomes Beverage Industry Veteran Todd Grice as General Counsel1.10.2020 14:15:00 CESTPress release

Bacardi Limited, the world’s largest privately held spirits company, today announces the appointment of Todd Grice as Senior Vice President and General Counsel. Grice brings 25 years of legal practice to Bacardi, including the last 18 with The Coca-Cola Company, with extensive business and legal expertise in corporate governance, competition law, securities law, intellectual property, mergers and acquisitions, and commercial transactions. This appointment follows the long-planned retirement of Eduardo Sanchez who served as the company’s SVP and General Counsel for 17 years. Grice will report to Chief Executive Officer Mahesh Madhavan and joins the company’s Global Leadership Team. At Bacardi, Grice will be responsible for legal and government affairs including legal strategy, governance and compliance, strategic transactions, and dispute resolution and regulatory matters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201001

ExaGrid Nominated in Seven Categories for the 2020 Storage Awards1.10.2020 14:00:00 CESTPress release

ExaGrid®, the industry’s only Tiered Backup Storage solution, today announced that it has been nominated in seven categories for the 17th annual Storage Awards. ExaGrid has become a finalist for Contribution to the Storage Industry, Hyper-convergence Vendor of the Year, Enterprise Backup Hardware Company of the Year, Storage Innovators of the Year, Storage Performance Optimisation Company of the Year, Storage Product of the Year, and Storage Company of the Year. Voting to determine the winner in each category is underway now and closes on November 12. Winners of this year’s awards will be announced on November 26, 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201001005189/en/ While ExaGrid has been recognized in five award categories as a company, its product line, the EX Series of Tiered Backup Storage appliances, is also nominated in the Storage Product of the Year category, and this year is especially unique as Exa

IT Departments that aren’t Listening to Employees Will Fail in 2021, says 1E1.10.2020 13:14:00 CESTPress release

Endpoint automation leader 1E has announced new features to their market leading digital experience management offering, Tachyon Experience, helping enterprises truly understand how users experience their IT. Sentiment as a leading indicator in a Remote First World In a remote first world, knowledge workers increasingly rely on their endpoint to be performant and responsive; The endpoint is their entire conduit to the workplace. Recent research by Vanson Bourne showed that the overwhelming majority (98%) of remote workers found endpoint performance to be important, yet more than half (53%) saying that their machine runs more slowly outside the office. IT has historically lacked the tools to identify and remediate these issues. Tachyon Experience has been built to provide IT analytics of the aggregated digital experience of users across the entire endpoint estate down to the sentiment of an individual user. “Almost every knowledge worker is working remotely, but they have an inferior ex

DIMOCO Notifies German Mobile Network Operators Telefónica Germany, Telekom and Vodafone as Payment Agents1.10.2020 13:05:00 CESTPress release

Since January 2018, mobile network operators (MNOs) are obliged to operate under the telecommunication exemption of PSD2 regulation, entitling them to only process digital goods, ticketing, parking and charities, but restricts them to extend the billing of goods and services outside the telecommunication exemption. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201001005598/en/ DIMOCO Presse Release: DIMOCO notifies German Mobile Network Operators Telefónica Germany, Telekom and Vodafone as Payment Agents (Graphic: Business Wire) The DIMOCO agent model enables MNOs to operate under the company’s financial license, enabling them to process payments for goods and services outside this exemption. DIMOCO, a leading provider for direct MNO connections in Europe, currently obtains 210 MNO connections in 48 countries, covering 90 percent of Europe. Since 2016, DIMOCO operates under its payment license, granted by the Austrian Finan

Temenos Names Roger Klantschi EVP of Delivery for the Americas to Drive Customer Business Value and Success1.10.2020 13:00:00 CESTPress release

Temenos (SIX: TEMN), the banking software company, today announced that Roger Klantschi has been appointed as Executive Vice President of Delivery, Americas, effective immediately. In this new role, Roger will be leading Services and Support for North America and Latin America & Caribbean, with a focus on building customer value and success in the region. Roger will report directly to Alexa Guenoun, President, Americas, and Global Head of Partners, Temenos. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201001005069/en/ Roger Klantschi (Photo: Business Wire) Temenos has identified the Americas as a strategic region, and has invested over US$1 billion in the past few years acquiring leading US-based SaaS companies such as Kony and Avoka. Temenos has 1300 clients in North America ranging from large nationals to regional banks to credit unions, de novo banks and fund administrators. Temenos also has over 100 clients in LATAM &

BIAL Goes Global With New US Research Center and Acquisition of Promising Parkinson's Disease Programs1.10.2020 13:00:00 CESTPress release

BIAL, a pharmaceutical company based in Portugal with locations across Europe and dedicated to R&D in CNS diseases, announced today that it has established a new affiliate in the United States of America, BIAL Biotech Investments Inc. (BIAL Biotech). This new research center focused on genetically-defined Parkinson’s disease is based in Cambridge, Massachusetts, a prominent biotech hub in the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201001005323/en/ Simultaneously, BIAL announced that it has acquired worldwide rights of LTI-291 and all the Parkinson’s disease research programs of Lysosomal Therapeutics Inc. (LTI) and taken on the entire R&D team. António Portela, executive president of BIAL, reveals: “Our entry into the US with the creation of BIAL Biotech and the acquisition of the promising programs from LTI, is a decisive step towards the fulfilment of our mission to contribute to improving the quality of lif

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom